Overview

A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are: to confirm the superiority of TAU-284 over placebo after two weeks of administration to pediatric patients with perennial allergic rhinitis, and to investigate the dose response, safety, and plasma concentrations of TAU-284.
Phase:
Phase 3
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma Corporation
Treatments:
Bepotastine besilate